• UBS updated its rating for NASDAQ:WBA to Neutral with a stock price of $11.31.
• Expected third-quarter earnings of 34 cents per share, with revenue projected to rise to $36.72 billion.
• Walgreens agreed to pay $300 million to settle federal allegations, impacting stock performance.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is a global leader in retail and wholesale pharmacy, operating in over 25 countries and offering a wide range of health and wellness products. Competing with major pharmacy chains like CVS Health and Rite Aid, Walgreens has been a key player in the pharmaceutical industry. On June 26, 2025, UBS updated its rating for WBA to Neutral, maintaining a hold action, with the stock priced at $11.31, as reported by Benzinga.

Walgreens is set to release its third-quarter earnings results, with analysts expecting earnings of 34 cents per share, a drop from 63 cents per share last year. Despite this decrease, revenue is projected to rise slightly to $36.72 billion from $36.35 billion. This mixed financial outlook may have influenced UBS's decision to maintain a Neutral rating.

Recent legal issues have also impacted Walgreens' stock performance. The company agreed to pay $300 million to settle federal allegations related to invalid prescriptions for opioids and other controlled substances. This settlement likely affected investor sentiment, contributing to a 0.4% decline in the stock price, closing at $11.31.

The stock has experienced a slight decrease of 0.35% today, with a change of $0.04. It traded between $11.31 and $11.36, reflecting some volatility. Over the past year, WBA's stock has seen a high of $13.25 and a low of $8.08, with a market capitalization of approximately $9.79 billion.

For those interested in analyst perspectives, Benzinga offers access to the latest analyst ratings. This allows investors to sort by stock ticker, company name, analyst firm, and other variables, providing valuable insights into Walgreens' market position and future prospects.